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Abstract
Background: Alcohol dependence comorbid with major depressive disorder poses a major challenge in the clinical
setting. The results in the treatment with selective serotonin re-uptake inhibitors have been conflicting. Thus, we
compared in alcohol-dependent patients with co-morbid major depressive disorder the selective serotonin re-uptake
inhibitor escitalopram to a compound that acts on different transporter system and may reduce craving, the glutamate
receptor antagonist memantine.
Methods: Eighty alcohol-dependent patients comorbid with major depressive disorder in municipal alcohol clinics were
randomized 1:1 to receive memantine 20 mg or escitalopram 20 mg in a double-blind manner. During the 26-week study
period patients continued their routine treatment at the clinics. Abstinence was not required but encouraged. The
patients attended visits weekly during the first month, and then at 3 and at 6 months. Outcome measures were Alcohol
Use Disorders Identification Test (AUDIT), Obsessive Compulsive Drinking Scale (OCDS) and Drinking Diary.
Results: The completion rate was high in both groups, especially among the patients who had been abstinent at the
beginning of the study. However, among those patients who were not abstinent at baseline, 47% in both groups
discontinued the study. Numbers of abstinent days were high in both groups throughout the study. Alcohol consumption
measured by the AUDIT QF (quantity-frequency) score was significantly reduced in both groups, as was the craving for
alcohol measured by the OCDS. Early age at first alcohol intoxication predicted poor treatment outcomes in patients
treated with escitalopram, and the same was seen with the early onset of the first depressive episode. The same
predictive effects were not found in patients treated with memantine.
Conclusion:  Our results indicate that both memantine and escitalopram are useful adjunct medications for the
treatment of alcohol dependence co-morbid with major depression. Memantine was at least as effective with regard to
drinking as escitalopram. We believe that a direct comparison of memantine, with the commonly used escitalopram, can
provide useful information for clinicians on the treatment of alcohol dependency co-morbid with MDD.
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Background
The lifetime prevalence of alcohol dependence as well as
co-morbidity with depressive disorders is high. For exam-
ple, the lifetime prevalence of alcoholism was 5.4% in the
United States among individuals over the age of 18 years
according to the National Comorbidity Survey Replica-
tion (NCS-R)[1]. Among these alcohol-dependent
patients, co-morbidity with depressive disorders was
24.3% in men and 48.5% in women [2]. Alcohol-depend-
ent patients who are co-morbid for major depressive dis-
order (MDD) constitute a patient group whose
pharmaceutical treatment has been particularly difficult
[3].
It has been proposed that SSRIs are most beneficial for the
treatment of alcohol dependence [17,18]. However, the
results are inconsistent. Some studies supported the effi-
cacy of zimilidine and citalopram in alcoholics [18-20]. In
alcoholism without depression, SSRIs have shown posi-
tive results in cases of less severe drinking [5,21]. In some
studies SSRIs were found even to be worse than placebo
[22,23] especially when treating early onset (Type B, Type
II) subtypes of alcoholics [24,25]. Treatment with SSRIs
for alcohol dependence with co-morbid major depressive
disorder (MDD), however, has generally produced posi-
tive results [11,12,26]. Escitalopram, the S-enantiomer of
citalopram, is the most selective of the SSRI antidepres-
sants [27]. It is now widely used for the treatment of
depression [20]. In a recent review escitalopram was
found to have the highest efficacy among antidepressants
in the treatment of severe depression [28] but there are no
studies on escitalopram in the treatment of MDD comor-
bid with alcohol dependence.
Acamprosate is a weak NMDA modulator which acts as an
antagonist at the mGluR5 metabotropic glutamate recep-
tor [29]. Acamprosate is approved in many countries for
the treatment of alcohol dependence [30] although some
recent studies [31,32] have not found significant benefits.
Memantine is a non-competitive ionotropic NMDA recep-
tor blocker. It is FDA approved for the treatment of mod-
erate to severe Alzheimer's disease [33]. Memantine has
been shown to block ethanol-induced up-regulation of
NMDA receptors [34]. Rat studies have shown that
memantine may reduce alcohol craving [35-39]. Recent
clinical studies show that memantine may suppresses the
craving for alcohol in moderate drinkers when deprived,
but not when drinking [40]. In recovering alcohol-
dependent patients memantine seemed to reduce craving
[41], while in actively drinking alcohol-dependent non-
depressive patients, memantine did not reduce craving or
alcohol consumption [42]. The studies of memantine in
the treatment of depression are rare: when treated ther-
apy-resistant depressive patients, Zarate did not find any
recovering [43], while in our recent study, memantine was
comparable with escitalopram in the treatment of major
depression comorbid with alcohol dependence [44]. We
hypothesized that the NMDA receptor antagonist
memantine may reduce also craving and alcohol con-
sumption in depressive alcoholics. The aim of this study
was to compare effects of NMDA receptor antagonist
memantine to escitalopram on alcohol consumption, in a
natural sample of treatment-seeking alcohol-dependent
patients (both actively drinking and recovering) with
comorbid MDD. The possible predictors for treatment
outcomes were studied also.
Methods
Study participants
Men and women aged 26 to 65 years who were voluntarily
seeking outpatient treatment for alcohol problems at
three Helsinki municipal Alcohol-clinics (A-clinics).
Patients with a history of heavy drinking (averaging five or
more daily drinks for men and four or more daily drinks
for women) for at least ten years, significant depression
defined by the Beck Depression Inventory II (BDI-II > 16),
and who were interested in voluntarily taking part in the
study were recommended by their A-clinic doctor or social
worker therapist to be interviewed and screened by the
study physician. The patients were interviewed by the
study doctor (psychiatrist LM) applying the Structured
Clinical Interview for DSM- IV (SCID) and were required
to meet the criteria of both alcohol dependence and MDD
according to DSM-IV-TR. Abstinence was not required but
encouraged. The time since the last prior inpatient detoxi-
fication had to be at least four weeks. In addition, the eli-
gible patients had to be currently in a depressive episode
lasting for more than two weeks. The exclusion criteria
included other substance use dependence screened by
urine test (amphetamine, benzodiazepines, cocaine, tet-
rahydrocannabinol and opiates, schizophrenia or other
psychotic disorder, and bipolar I and II disorder, acute risk
of suicide, pregnancy or breastfeeding, a severe untreated
somatic problem, or a serious dysfunction of the liver
(aspartate aminotransferase [AST] and alanine ami-
notransferase [ALT] > 200), and mental disability. Other
medications prescribed by participants' physicians were
allowed, with the exception of other antidepressants. All
patients were Caucasian, and 55% were men. There were
no significant differences between the groups in either
their demographic characteristics or their initial alcohol
and depressive measures [44]. The mean length of the
present depressive period was 35 months. Current alcohol
use was reported by 17 patients (43.6%) in the meman-
tine group and 17 (42.5%) in the escitalopram group. The
number of A-clinic visits (psychosocial counseling) dur-
ing the study period was similar: in the memantine group
7.7 ± 8.8 (mean ± SD) and in the escitalopram group 7.1
± 9.2. [44].Substance Abuse Treatment, Prevention, and Policy 2008, 3:20 http://www.substanceabusepolicy.com/content/3/1/20
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All 58 subjects who completed the study attended all
appointments and showed at least 80% compliance based
on tablet counts. The average consumption (mg) of med-
ication did not differ between the two medication groups:
during the first 12 weeks, for memantine 17.4 ± 0.5 mg
and for escitalopram 16.9 ± 0.6 mg; and during weeks 13–
26, for memantine 17.4 ± 0.6 mg and for escitalopram
15.9 ± 0.8 mg.
Ethics
The study was approved by the independent Hospital Dis-
trict of Helsinki and Uusimaa, Ethical Committee (per-
mission 22/2004) and the Finnish National Agency of
Medicine (KL# 87/2004). The study was conducted
according the ICH Guidelines for Good Clinical Practice
and the 1964 Declaration of Helsinki. The study was reg-
istered on the National Public Health study registry in
March, 2005 (172–9), and the ClinicalTrials.gov Identi-
fier (trial # NCT00368862). All patients had to be able to
read and understand the patient information sheet and
sign the informed consent. All participants were free to
stop the study medication whenever they wanted. The
patients were not paid or otherwise reimbursed for partic-
ipation.
Study design
Eighty-nine patients were initially screened. A screening
interview (SCID) was conducted to confirm the diagnoses
of MDD and alcohol dependence. Patients completed
questionnaires including the Obsessive-Compulsive
Drinking Scale (OCDS [45]) and the Alcohol Use Disor-
ders Identification Test (AUDIT) [46]. AUDIT-QF [47],
and AUDIT-3 [48] were used for a detailed drinking anal-
ysis. The recording of alcohol consumption during the 26-
week treatment period was done with a personal drinking
diary for all days, including abstinent days [49].
All patients meeting the inclusion criteria were randomly
assigned to the memantine or escitalopram group using a
1:1 ratio (n = 40 + 40). Eligible patients received orally
either 20 mg/day escitalopram or 20 mg/day memantine.
The starting dose was 5 mg/day for both drugs and was
increased at weekly intervals by 5 mg/day to 20 mg/day.
Patients were instructed to take the study medication in
the morning. Patients were permitted to telephone the
study physician at any time. If the patient did not appear
at a scheduled visit, a new appointment was offered.
During the 26-week treatment period, the patients
returned to the study site at weeks 1, 2, 4, 12 ± 2, and 26
± 2 for data collection and for medication checking and
dispensing. At each visit, the drinking diary and the study
medication intake since the previous visit were recorded
from the medication diary. The study medication was
ensured by pill count from the returned blister-packs.
Outcomes were recorded on specific weeks: OCDS (weeks
0, 4, 12 and 26); AUDIT (week 0, 12 and 26, the later ones
modified to report the events in the previous month).
Clinical laboratory tests (MCV, AST, ALT, CDT, and GGT)
were taken at the beginning of the study and were
repeated at weeks 4, 12, and 26, to ensure the safety of the
medication. No breath or blood test for alcohol was per-
formed, but if the patient was obviously intoxicated, a
new appointment was offered. The study was monitored
by an independent organization, Medikalla Oy, Medfiles,
Turku.
Statistical analysis
All primary and secondary outcome statistical analysis
was performed by an independent source (Medikalla Oy,
MedFiles, Turku). All statistical evaluation utilized SAS
Procedures in SAS® system for Windows (Version 8.2),
SAS-institute, Espoo, Finland.
Intent-to-treat sample, which included all randomized
patients including two patients who discontinued early in
the study and reported, taking no medication, were used
in all tables and analyses. Descriptive statistics were calcu-
lated for all variables. Categorical variables were presented
in frequencies tables (number of cases and percentages)
by treatment. The numerical variables were tabulated by
treatment. Baseline measures were analyzed by logistics
regression or analysis of variance. All repeated dependent
measures (drinking diary, OCDS, AUDIT, laboratory
tests), were analyzed with analysis of variance for repeated
measures (ANOVA) when treatment, time, and treatment
* time interaction were in the model (PROC MIXED in
SAS®) and responses to the specific question (Has your
alcohol use diminished during the study?) were analyzed
by logistic regression (PROG LOGOSTIC in SAS®).
Furthermore, predictors of treatment response by medica-
tion were analyzed with multiple linear regression analy-
ses by adjusting for the baseline OCDS and AUDIT scores.
Results
The drop out ratio was similar in the two groups: 11 out
of 40 patients (27.5%) discontinued the study before the
end of the 26-week period in both the memantine and the
escitalopram groups. Two patients in both treatment
groups (6.9%) used disulfiram, and one patient in both
groups (3.4%) used a mood stabilizer.
Alcohol consumption
The baseline AUDIT and alcohol use histories are similar
in both groups (Table 1). AUDIT scores decreased (Fig. 1)
from baseline in both groups, from 27.4 ± 7.1 to 14.3 ±
9.9 in the memantine group and from 28.4 ± 6.4 to 17.6
± 10.4 in the escitalopram group. The overall reduction
was highly significant (F [2.77] = 48.42, p < .0001) in bothSubstance Abuse Treatment, Prevention, and Policy 2008, 3:20 http://www.substanceabusepolicy.com/content/3/1/20
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groups combined. The treatment by time interaction was
not significant (F [2.77] = 1.19, p = 0.31).
Alcohol consumption measured by the AUDIT QF (quan-
tity-frequency) score was significantly reduced in both
groups: in the memantine group from 6.2 ± 1.7 to 4.1 ±
2.5 and from 6.1 ± 1.7 to 4.3 ± 2.3 in the escitalopram
group (F [2.77] = 23.53, p < .0001). The treatment by time
interaction was not significant (F [2.77] = 1.58, p = 0.21).
The number of heavy drinking days measured by the
AUDIT-3 score was also diminished significantly in both
groups: for the memantine group from 2.9 ± 1.1 to 1.8 ±
1.3 and from 3.1 ± 1.0 to 2.4 ± 1.3 for the escitalopram
group (F [2.77] = 20.29, p > .0001). The treatment by time
interaction was not significant (F [2.77] = 1.37, p = 0.27).
The number of abstinent days per week was high for both
groups throughout the study. The treatment by time inter-
action in the number of abstinent days per week was not
significant (F [2.74] = 0.07, p = 0.93) (Figure 2). The mean
alcohol intake including abstinent days was 15.0 ± 2.6 g
per day for the memantine group and 21.1 ± 3.6 g per day
for the patients on escitalopram, with no significant dif-
ference between the groups (F [1.74] = 1.94, p = 0.17).
When questioned at the end of the intervention, 68.9% of
the patients in the memantine group reported their alco-
hol use had decreased while 62.1% of the patients in the
escitalopram group reported a decrease.
Indicators of craving for alcohol
The OCDS total scores (Fig. 3) decreased in the meman-
tine group from 18.8 ± 6.9 to 10.6 ± 7.2 and in the escita-
lopram group from 20.4 ± 4.9 to 12.8 ± 8.6. The overall
reduction was highly significant (F [3.77] = 25.76, p <
.0001) in both groups combined. The treatment by time
interaction in the OCDS was not significant (F [3.77] =
0.69; p = 0.56).
In both groups, the mean serum concentrations of AST,
ALT, GGT, and CDT were within normal limits, and there
were no significant changes during the treatment period
or any significant differences between the groups. The
adverse events during the study are published in our pre-
vious article [44]. There was no significant difference in
reporting adverse events between the medication groups.
Predictors of the treatment outcomes
In general, those patients who were abstinent at the begin-
ning of treatment were more likely to complete the treat-
ment than those who were still drinking at the beginning
Table 1: Demographic backgrounds. 
Variable Memantine (n = 40) Escitalopram (n = 40)
Age (years, mean ± SD) 47.5(± 8.3) 47.9(± 8.3)
Gender, male (n, %) 23 (57.5) 21 (52.5)
First alcohol intoxication, (age, mean ± SD) 15.3 (± 3.8) 15.4 (± 2.3)
Onset of regular use of alcohol (age, mean ± SD) 20.7(± 6.7) 20.5 (± 6.3)
Onset of alcohol abuse (age mean ± SD) 29.5(± 8.1) 28.3(± 8.3)
Onset of alcohol dependence (age, mean ± SD) 30.6 (± 8.3) 29.1(± 8.5)
Audit baseline (mean ± SD) 27.4 (± 1.1) 28.4 (± 1.0)
No abstinence before study initiation (n, %) 17 (43.6) 17 (42.5)*
Alcohol problems among relatives (n, %), 31 (79.5)* 30 (76.9)*
Montgomery-Asberg depression rating scale (MADRS) baseline scores 25.8(± 4.4) 26.8 (± 4.1)
First depressive episode (age, mean ± SD) 27.8(± 12.3) 24.2 (± 13.0)
Total number of depressive episodes (mean ± SD) 10.0(± 7.1) 9.6(± 9.0)
There were no significant differences between the groups on any of the baseline socio-demographic background measures.
*missing information in one patient
Change in alcohol use measured by the AUDIT scores Figure 1
Change in alcohol use measured by the AUDIT 
scores. §§§Significant reduction from base values prior to 
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(χ2 = 6.51, df = 1, p = 0.011). This relationship was highly
significant in the patients treated with memantine (χ2 =
7.25, df = 1, p = 0.007): 8 of the 11 who dropped out were
among the 17 (47.1%) who were active drinkers at the
baseline. The relationship was in the same direction in the
escitalopram group but failed to reach statistical signifi-
cance (χ2 = 0.901, df = 1, p = 0.343).
We tested by multiple linear regression analyses whether
age at onset of depression and age at first alcohol intoxi-
cation predicted change during the six month treatment in
the OCDS and the AUDIT scores. Age at onset of depres-
sion predicted differently change in the OCDS in the esci-
talopram group compared with the memantine group (R2
change for interaction term = 0.05; p for treatment by age
at onset of depression interaction = 0.05). In the escitalo-
pram group, earlier onset of depression predicted less
change in the OCDS scores during the six months (B = -
0.31, 95% CI = -0.53 to -0.09, p = 0.008) whereas in the
memantine group no such association existed (B = -0.02,
95% CI = -0.22 to 0.17, p = 0.81). There were no differ-
ences between the medication groups in the association
between age at onset of depression and change in the
AUDIT (R2 change for interaction term = 0.02; p for inter-
action = 0.21) or in the association between age at first
alcohol intoxication and change in the OCDS and the
AUDIT (R2 change for interaction term < 0.022; p-values
for interactions > 0.21). Neither did age at onset of depres-
sion predict change in the AUDIT (B = -0.16, 95% CI = -
0.37 to 0.05, p = 0.12) or age at first alcohol intoxication
predict change in the OCDS (B = -0.68, 95% CI = -1.41 to
0.05, p = 0.07) and the AUDIT (B = -0.24, 95% CI = -1.62
to 1.13, p = 0.72) in the subjects when both treatment
groups were combined.
Discussion
Citalopram and escitalopram have been used in the treat-
ment of alcohol dependence especially when co-morbid
with major depressive disorder. Treatment outcomes with
other SSRIs have not been consistent [3,15,26,50-53]. In
our study, both memantine and escitalopram patients
reported reduced alcohol craving and consumption, and
patient compliance was good. However, the two study
groups did not differ in alcohol craving, obsessive
thoughts of drinking, compulsive drinking, alcohol con-
sumption, maintaining abstinence, and number of absti-
nent days per week. Our study corroborates a recent study
by Krupitsky et al. [41], who reported that memantine
reduced alcohol cue-induced craving in recovering alco-
holics.
Few possible predictive elements for the treatment of alco-
hol dependence comorbid with major depressive disorder
with either escitalopram or memantine were observed.
The abstinence at the beginning of the treatment pre-
dicted more likely the continuing of the treatment, espe-
cially in the memantine group. Evans et al. [42] found no
effect of memantine in patients who were actively drink-
ing at the beginning of treatment, which may explain our
findings that such patients had a higher dropout rate than
those who were abstinent at the start of treatment. Other
predictor observed was the early age at onset of the first
depressive episode, which leads to poor treatment out-
come with escitalopram but not with memantine. How-
Mean number of abstinent days per week Figure 2
Mean number of abstinent days per week. No statisti-
cally significant difference between the treatment groups in 
mean number of days ± SD.
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ever, due to multiple testing without a priori hypothesis,
this difference should be interpreted with caution.
Our study has several limitations. It is a comparative study
of two medications and is limited by the absence of a pla-
cebo group. Both treatment groups improved significantly
and a placebo-effect could be significant in both groups,
as has been observed in earlier studies [52]. Spontaneous
recovery and intermittent periods of lower alcohol intake
are of typical in alcohol dependence [54,55]. Therefore,
we cannot determine whether the overall improvement in
the present study was due to the medications, and our
interpretations are limited to comparisons between
memantine and escitalopram. Detoxification and a cer-
tain period of abstinence could influence the results.
Another limitation is the rather small number of patients,
which may have been too low to detect a significant differ-
ence between the treatments. Socio-demographic indica-
tors correspond well to those generally found among
patients treated at Finnish A-clinics [56], suggesting that
the present material represents a relatively unbiased sam-
ple. The only difference observed was the higher percent-
age of women, which can probably be attributed to the
inclusion criterion of major depression. We did not
attempt to distinguish between patients with primary
depressive disorders and substance-induced depression.
This situation corresponds to that at the onset of treat-
ment; it is when the clinician has to decide which medica-
tions to prescribe. Our patients were treatment-seeking, so
the option of providing no active medication was not
accepted by either the treating professionals or the
patients.
Our finding may suggest that memantine could be useful
treatment for type one alcoholics (early onset) comorbid
with depression. The finding that the early onset of the
first depressive episode is a negative predictor for escitalo-
pram treatment in alcohol dependence confirms our pre-
vious finding on treatment of this comorbidity regarding
major depressive disorder in patients with this dual diag-
nosis [57].
It may be concluded that memantine seems comparable
to escitalopram and could be used as well as escitalopram
in the treatment of alcohol dependence comorbid with
major depression. The results, therefore, warrant further
studies of memantine in patients with alcohol depend-
ence comorbid with major depression as well as of predic-
tive signs of treatment outcome. However, because of the
small number of study patients and the conventional sta-
tistics, the results should be taken with caution.
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